FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385622645> ?p ?o ?g. }

• W4385622645 endingPage "1056" @default.
• W4385622645 startingPage "1047" @default.
• W4385622645 abstract "Background: In 2019, the U.S. Food and Drug Administration (FDA) approved the first generic maintenance inhaler for asthma and chronic obstructive pulmonary disease (COPD). The inhaler, Wixela Inhub (fluticasone–salmeterol; Viatris), is a substitutable version of the dry powder inhaler Advair Diskus (fluticasone–salmeterol; GlaxoSmithKline). When approving complex generic products like inhalers, the FDA applies a special “weight-of-evidence” approach. In this case, manufacturers were required to perform a randomized controlled trial in patients with asthma but not COPD, although the product received approval for both indications. Objective: To compare the effectiveness and safety of generic (Wixela Inhub) and brand-name (Advair Diskus) fluticasone–salmeterol among patients with COPD treated in routine care. Design: A 1:1 propensity score–matched cohort study. Setting: A large, longitudinal health care database. Patients: Adults older than 40 years with a diagnosis of COPD. Measurements: Incidence of first moderate or severe COPD exacerbation (effectiveness outcome) and incidence of first pneumonia hospitalization (safety outcome) in the 365 days after cohort entry. Results: Among 45 369 patients (27 305 Advair Diskus users and 18 064 Wixela Inhub users), 10 012 matched pairs were identified for the primary analysis. Compared with Advair Diskus use, Wixela Inhub use was associated with a nearly identical incidence of first moderate or severe COPD exacerbation (hazard ratio [HR], 0.97 [95% CI, 0.90 to 1.04]) and first pneumonia hospitalization (HR, 0.99 [CI, 0.86 to 1.15]). Limitations: Follow-up times were short, reflecting real-world clinical practice. The possibility of residual confounding cannot be completely excluded. Conclusion: Use of generic and brand-name fluticasone–salmeterol was associated with similar outcomes among patients with COPD treated in routine practice. Primary Funding Source: National Heart, Lung, and Blood Institute." @default.
• W4385622645 created "2023-08-08" @default.
• W4385622645 creator A5036726043 @default.
• W4385622645 creator A5041217714 @default.
• W4385622645 creator A5048211823 @default.
• W4385622645 creator A5074257304 @default.
• W4385622645 creator A5085213521 @default.
• W4385622645 date "2023-08-01" @default.
• W4385622645 modified "2023-09-23" @default.
• W4385622645 title "Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone–Salmeterol to Treat Chronic Obstructive Pulmonary Disease" @default.
• W4385622645 cites W1484947420 @default.
• W4385622645 cites W1501511408 @default.
• W4385622645 cites W1967862917 @default.
• W4385622645 cites W2087018232 @default.
• W4385622645 cites W2170215820 @default.
• W4385622645 cites W2170591838 @default.
• W4385622645 cites W2295597785 @default.
• W4385622645 cites W2365138737 @default.
• W4385622645 cites W2554373806 @default.
• W4385622645 cites W2589722268 @default.
• W4385622645 cites W2715795126 @default.
• W4385622645 cites W2771285175 @default.
• W4385622645 cites W2802221596 @default.
• W4385622645 cites W2831840344 @default.
• W4385622645 cites W2897466202 @default.
• W4385622645 cites W2898780621 @default.
• W4385622645 cites W2924400461 @default.
• W4385622645 cites W2981742323 @default.
• W4385622645 cites W2987024673 @default.
• W4385622645 cites W3003762148 @default.
• W4385622645 cites W3007383981 @default.
• W4385622645 cites W3023340082 @default.
• W4385622645 cites W3037411127 @default.
• W4385622645 cites W3082058325 @default.
• W4385622645 cites W3115509726 @default.
• W4385622645 cites W3138310799 @default.
• W4385622645 cites W3211658667 @default.
• W4385622645 cites W337842491 @default.
• W4385622645 cites W4214952140 @default.
• W4385622645 cites W4280621377 @default.
• W4385622645 cites W4293575919 @default.
• W4385622645 cites W4313532816 @default.
• W4385622645 doi "https://doi.org/10.7326/m23-0615" @default.
• W4385622645 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37549393" @default.
• W4385622645 hasPublicationYear "2023" @default.
• W4385622645 type Work @default.
• W4385622645 citedByCount "0" @default.
• W4385622645 crossrefType "journal-article" @default.
• W4385622645 hasAuthorship W4385622645A5036726043 @default.
• W4385622645 hasAuthorship W4385622645A5041217714 @default.
• W4385622645 hasAuthorship W4385622645A5048211823 @default.
• W4385622645 hasAuthorship W4385622645A5074257304 @default.
• W4385622645 hasAuthorship W4385622645A5085213521 @default.
• W4385622645 hasConcept C126322002 @default.
• W4385622645 hasConcept C177713679 @default.
• W4385622645 hasConcept C1862650 @default.
• W4385622645 hasConcept C207103383 @default.
• W4385622645 hasConcept C2776042228 @default.
• W4385622645 hasConcept C2776136866 @default.
• W4385622645 hasConcept C2776719499 @default.
• W4385622645 hasConcept C2776780178 @default.
• W4385622645 hasConcept C2777014857 @default.
• W4385622645 hasConcept C2779028295 @default.
• W4385622645 hasConcept C2779871671 @default.
• W4385622645 hasConcept C2780261241 @default.
• W4385622645 hasConcept C2781212218 @default.
• W4385622645 hasConcept C44249647 @default.
• W4385622645 hasConcept C71924100 @default.
• W4385622645 hasConcept C72563966 @default.
• W4385622645 hasConceptScore W4385622645C126322002 @default.
• W4385622645 hasConceptScore W4385622645C177713679 @default.
• W4385622645 hasConceptScore W4385622645C1862650 @default.
• W4385622645 hasConceptScore W4385622645C207103383 @default.
• W4385622645 hasConceptScore W4385622645C2776042228 @default.
• W4385622645 hasConceptScore W4385622645C2776136866 @default.
• W4385622645 hasConceptScore W4385622645C2776719499 @default.
• W4385622645 hasConceptScore W4385622645C2776780178 @default.
• W4385622645 hasConceptScore W4385622645C2777014857 @default.
• W4385622645 hasConceptScore W4385622645C2779028295 @default.
• W4385622645 hasConceptScore W4385622645C2779871671 @default.
• W4385622645 hasConceptScore W4385622645C2780261241 @default.
• W4385622645 hasConceptScore W4385622645C2781212218 @default.
• W4385622645 hasConceptScore W4385622645C44249647 @default.
• W4385622645 hasConceptScore W4385622645C71924100 @default.
• W4385622645 hasConceptScore W4385622645C72563966 @default.
• W4385622645 hasFunder F4320337338 @default.
• W4385622645 hasIssue "8" @default.
• W4385622645 hasLocation W43856226451 @default.
• W4385622645 hasLocation W43856226452 @default.
• W4385622645 hasOpenAccess W4385622645 @default.
• W4385622645 hasPrimaryLocation W43856226451 @default.
• W4385622645 hasRelatedWork W1986046118 @default.
• W4385622645 hasRelatedWork W2003706075 @default.
• W4385622645 hasRelatedWork W2032558045 @default.
• W4385622645 hasRelatedWork W2075905701 @default.
• W4385622645 hasRelatedWork W2080945474 @default.
• W4385622645 hasRelatedWork W2145584026 @default.
• W4385622645 hasRelatedWork W2154436876 @default.

• next